Новые подходы в лечении лекарственно - устойчивого туберкулеза
DOI:
https://doi.org/10.52692/1857-0011.2024.2-79.38Ключевые слова:
туберкулез, ТБ МЛУ, лечениеАннотация
Туберкулез с множественной лекарственной устойчивостью (МЛУ ТБ), резистентный к изониазиду и рифампицину, остается одной из важнейших угроз для контроля эпидемии туберкулеза. За последние несколько лет в парадигме лечения МЛУ ТБ произошли многообещающие сдвиги: новые препараты показали активность против Mycobacterium tuberculosis (MBT), а несколько коротких схем лечения МЛУ ТБ показали многообещающие результаты. Целью данного комплексного обзора является обобщение рекомендуемых ВОЗ схем лечения МЛУ ТБ, а также изложение новых взглядов на лечение пациентов с МЛУ ТБ.
Библиографические ссылки
World Health Organization Implementing the End TB Strategy. Antimicrob. Agents Chemother. 2014; 58:7250–7257.
World Health Organization Regional Office for Europe. Roadmap to prevent and combat drug- resistant tuberculosis: the Consol idated Action Plan to Prevent and Combat Multidrug- and Ex tensively Drug-Resistant Tuberculosis in the WHO European Region, 2011–2015 5 p.
European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and mon itoring in Europe 2023–2021 data. Stockholm, Sweden; and Copenhagen, Denmark: ECDC & WHO Regional Office for Europe, 2023, 15 p.
Kohler S, et al. The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer,shorter, and short drug regimens for Karakalpakstan, Uzbekistan. PLoS Glob Public Health 2022;2(8): e0000567.
World Health Organization. WHO Treatment of Tuberculosis Guidelines. 4th ed. World Health Organization; Geneva, Switzerland: 2010, 84 p.
Falzon D., Schünemann H.J., Harausz E., González- Angulo L., Lienhardt C., Jaramillo E., Weyer K. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur. Respir. J. 2017; 49:1602308.
van Deun A., Maug A.K.J., Salim M.A.H., Das P.K., Sarker M.R., Daru P., Rieder H.L. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2010; 182:684–692.
Piubello A., Harouna S.H., Souleymane M.B., Boukary I., Morou S., Daouda M., Hanki Y., van Deun A. High cure rate with standardised short-course multidrug- resistant tuberculosis treatment in Niger: No relapses. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Against Tuberc. Lung Dis. 2014; 18:1188–1194.
Kuaban C., Noeske J., Rieder H.L., Aït-Khaled N., Abena Foe J.L., Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Against Tuberc. Lung Dis. 2015; 19:517–524.
World Health Organization. Who Consolidated Guidelines on Tuberculosis. Module 4: Treatment— Drug-Resistant Tuberculosis Treatment. World Health Organization; Geneva, Switzerland: 2020, 12 p.
Rapid сcommunication: key changes to treatment of multidrug and rifampicin-resistant tuberculosis (MDR/RR-TB). Geneva: World Health Organization; 2018 (https://iris.who.int/handle/10665/275383).
WHO consolidated guidelines on tuberculosis. Module 4: Treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022, 6 p. (https://iris.who.int/handle/10665/365308).
Key updates to the treatment of drug-resistant tuberculosis: rapid communication, August 2024, 3 p. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/378472).
WHO Consolidated guidelines on drug-resistant tuberculosis treatment, WHO, 2019, 19 p. https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/
World Health Organization. Who Consolidated Guidelines on Tuberculosis. Module 4: Treatment — Drug-Resistant Tuberculosis Treatment. World Health Organization; Geneva, Switzerland: 2020, 41 p.
Загрузки
Опубликован
Лицензия
Copyright (c) 2025 Вестник Академии Наук Молдовы. Медицина
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
